StockData
Champions Oncology, Inc. logo

Champions Oncology, Inc. (CSBR) stock

CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026Score 10/30238% above fair value
$4.59−0.09 (-1.89%)

Close on Nov 17, 2026Market cap $63.91MP/E –Yield –

Champions Oncology operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Champions Oncology's operating cash flow for the twelve months ending Jul 31, 2026 was -$5.56M, down 172.5% year over year. For fiscal 2026 it was -$4.47M, down 160.5% from the year before. The highest annual figure on record is $7.39M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2026Apr 30, 2026-$4.47M-160.5%
FY2025Apr 30, 2025$7.39M–
FY2024Apr 30, 2024-$6.14M-254.5%
FY2023Apr 30, 2023$3.97M-38.9%
FY2022Apr 30, 2022$6.50M–
FY2021Apr 30, 2021-$1.68M-157.9%
FY2020Apr 30, 2020$2.91M+56.0%
FY2019Apr 30, 2019$1.86M–
FY2018Apr 30, 2018-$1.23M–
FY2017Apr 30, 2017-$2.84M–
FY2016Apr 30, 2016-$6.41M–
FY2015Apr 30, 2015-$9.63M–
FY2014Apr 30, 2014-$3.43M–
FY2013Apr 30, 2013-$4.30M–
FY2012Apr 30, 2012-$5.23M–
FY2011Apr 30, 2011-$54.00K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jul 31, 2026-$492.00K-182.0%
Q4 FY2026CQ1 2026Apr 30, 2026-$2.00M-129.1%
Q3 FY2026CQ4 2025Jan 31, 2026-$1.34M-373.3%
Q2 FY2026CQ3 2025Oct 31, 2025-$1.74M–
Q1 FY2026CQ2 2025Jul 31, 2025$600.00K+92.9%
Q4 FY2025CQ1 2025Apr 30, 2025$6.87M–
Q3 FY2025CQ4 2024Jan 31, 2025$490.00K–
Q2 FY2025CQ3 2024Oct 31, 2024-$283.00K-148.0%
Q1 FY2025CQ2 2024Jul 31, 2024$311.00K–
Q4 FY2024CQ1 2024Apr 30, 2024-$1.82M–
Q3 FY2024CQ4 2023Jan 31, 2024-$919.00K-158.4%
Q2 FY2024CQ3 2023Oct 31, 2023$589.00K-82.1%
Q1 FY2024CQ2 2023Jul 31, 2023-$3.99M–
Q4 FY2023CQ1 2023Apr 30, 2023-$692.00K-186.9%
Q3 FY2023CQ4 2022Jan 31, 2023$1.57M-63.0%
Q2 FY2023CQ3 2022Oct 31, 2022$3.29M+167.6%
Q1 FY2023CQ2 2022Jul 31, 2022-$195.00K-190.3%
Q4 FY2022CQ1 2022Apr 30, 2022$796.00K–
Q3 FY2022CQ4 2021Jan 31, 2022$4.26M+3053.3%
Q2 FY2022CQ3 2021Oct 31, 2021$1.23M+39.7%
Q1 FY2022CQ2 2021Jul 31, 2021$216.00K–
Q4 FY2021CQ1 2021Apr 30, 2021-$1.98M-177.8%
Q3 FY2021CQ4 2020Jan 31, 2021$135.00K-51.6%
Q2 FY2021CQ3 2020Oct 31, 2020$879.00K+144.2%
Q1 FY2021CQ2 2020Jul 31, 2020-$715.00K–
Q4 FY2020CQ1 2020Apr 30, 2020$2.55M+909.9%
Q3 FY2020CQ4 2019Jan 31, 2020$279.00K-76.9%
Q2 FY2020CQ3 2019Oct 31, 2019$360.00K+462.5%
Q1 FY2020CQ2 2019Jul 31, 2019-$279.00K-183.0%
Q4 FY2019CQ1 2019Apr 30, 2019$252.00K+2700.0%
Q3 FY2019CQ4 2018Jan 31, 2019$1.21M+171.9%
Q2 FY2019CQ3 2018Oct 31, 2018$64.00K-76.1%
Q1 FY2019CQ2 2018Jul 31, 2018$336.00K–
Q4 FY2018CQ1 2018Apr 30, 2018$9.00K-97.7%
Q3 FY2018CQ4 2017Jan 31, 2018$445.00K–
Q2 FY2018CQ3 2017Oct 31, 2017$268.00K+131.0%
Q1 FY2018CQ2 2017Jul 31, 2017-$1.95M–
Q4 FY2017CQ1 2017Apr 30, 2017$398.00K–
Q3 FY2017CQ4 2016Jan 31, 2017-$684.00K–
Q2 FY2017CQ3 2016Oct 31, 2016$116.00K–

More Champions Oncology figures

See a number that looks wrong?